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ABSTRACT 
Baker Cleanser Bitters (BCB) - a polyherbal formula commonly used in the treatment of dia-
betes, liver cirrhosis, kidney failure, rheumatism and arthritis was evaluated in an acute and 
sub-chronic toxicity study in Wistar albino rats. A single administration of BCB was given 
orally at the highest dose level of 2000 mg/kg body weight in the acute toxicity study. Signs 
of toxicity were observed every hour for the first 6 h and every day for 7 days. In the sub-
chronic oral toxicity study, BCB was administered to rats at doses of 50, 100 and 200 mg/kg 
body weight for 28 days. Mortalities, clinical signs, body weight changes, biochemical and 
haematological parameters were monitored during the study period. There were no mortalities 
or clinical signs observed in rats in the acute toxicity study. In the sub-chronic study in rats, 
daily oral administration of BCB at the dose of 200 mg/kg body weight resulted in a drop in 
percentage increase in body weight at the end of the 4th week. Alanine amino transferase 
(ALT), aspartate amino transferase (AST), fasting blood sugar and packed cell volume (PCV) 
decreased significantly (p≤0.05) whereas alkaline phosphatase (ALP), lactate dehydrogenase 
(LDH) and platelets increased significantly (p≤0.05) when compared to control. The high no-
observed adverse effects level (NOAEL) value of 2000 mg/kg body weight implies that the 
drug could be safe. The study also revealed that the polyherbal drug may have good hypogly-
cemic effects and favourable reducing effects on the cardiovascular risk factors and explains 
the basis for the continual use of this plant by traditional medical practitioners. 
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INTRODUCTION 
Herbal medicine or phytomedicine is 
recognized as the most common form of 
alternative medicine (Ogbonnia et al., 
2011). The World Health Organization 
(WHO) estimates that 80 % of the world's 
population relies on these “alternative” 
plant-based medicines as their primary 
medical intervention especially in the de-
veloping and in the developed countries 
where modern medicines are predominantly 
used (Rickert et al., 1999; Kroll and Shaw, 
2003; Ogbonnia et al., 2008). Over the 
years, the use of herbs in the treatment of 
illnesses has been very successful and its 
historic usage has been useful in drug dis-
covery development. Herbal prescriptions 
and natural remedies are commonly em-
ployed in developing countries for the 
treatment of various diseases, this practice 
being an alternative way to compensate for 
some perceived deficiencies in orthodox 
pharmacotherapy (Sofowora, 1989; Zhu et 
al., 2002). The popularity and availability 
of the traditional remedies have generated 
concerns regarding the safety, efficacy and 
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responsibility of practitioners using tradi-
tional remedies (Chan, 1995). Herbal reme-
dies are considered safer and less damaging 
to the human body than synthetic drugs 
(Alam et al., 2011). However, the lack of 
standardization has been a major concern 
regarding use of herbal medicines (Angell 
and Kassierr 1998; NIEHS, 1998). Al-
though herbal supplements may be consid-
ered to be safe, some are known to be toxic 
at high doses and others may have poten-
tially adverse effect after prolonged use. 
The general public is largely unaware that 
adverse health effects can be associated 
with the use of herbal supplements resulting 
from overdosing, contaminated formula-
tions to the inherent toxicity of the herbs of 
choice (Hazel et al., 1999). 
Baker Cleanser Bitters is a polyherbal 
formulation used for various ethnomedici-
nal purposes in Nigeria. The constituents of 
Baker Cleanser Bitters (Aloe vera, Acinos 
ravens, Chenopodium murale, Cinno-
amomum aromaticum, Citrus aurantifolia 
and purified water) have been studied ex-
tensively (Grieve, 1971; Crawford, 2009). 
Ethnomedicinally, 30 ml of the liquid prod-
uct is taken daily after meal preferable at 
night for seven days for the treatment of 
diabetes mellitus, waist pain, arthritis, 
rheumatism, infertility, liver cirrhosis, kid-
ney failure, problems as well as typhoid fe-
ver and haemorrhoids. The aim of this 
study was to evaluate the safety profile of 
the polyherbal anti-diabetic preparation 
Baker Cleanser Bitters commonly used in 
Nigeria after a single or 28-day repeated 
dosing on selected biochemical and haema-
tological parameters. 
 
MATERIALS AND METHODS  
Collection of samples  
The herbal remedy Baker Cleanser Bit-
ters (BCB), manufactured by Baker Water 
and Beverages Ventures situated at 3-4 Sam 
Balogun close, off May and Baker Avenue, 
Aina Estate, Egusi Village, opposite Can-
nan land, Otta, Ogun State, Nigeria was ob-
tained from Isaac Boro Park, Mile1, in Port 
Harcourt City LGA of Rivers State, Nige-
ria.  
 
Experimental animals  
Healthy Wistar albino rats of both sexes 
weighing between 120-150 g, obtained 
from the Animal House of the Department 
of Physiology, University of Nigeria, Enu-
gu Campus, Enugu State, Nigeria were used 
for the sub-chronic study. They were divid-
ed into four groups of 10 rats per group. 
Each group comprised of five (5) male and 
female rats respectively. The animals were 
housed in a cross-ventilated room and kept 
under standard environmental condition of 
12/12 h light/dark cycle. They were housed 
in polypropylene cages (5 animals per cage) 
and were fed with standard rat pellet and 
water ad libitum. They were allowed to ac-
climatization for 7 days to the laboratory 
conditions before the experiment. The ex-
periment was performed in accordance with 
the guidelines established by the European 
Community for the Care and Use of Labor-
atory Animals and were approved by Insti-
tutional Animal Ethical Committee (IAEC). 
 
Acute toxicity test 
Healthy Wistar albino rats of both sexes 
weighing between 120-150 g maintained 
under standard laboratory conditions were 
used for the acute toxicity test according to 
the Organization for Economic Cooperation 
and Development (OECD) guidelines 423 
(OECD guideline, 2002). A total of ten an-
imals of equal numbers of male and female 
rats were used and each received a single 
oral-dose of 2000 mg kg-1 body weight of 
BCB. Animals were kept overnight fasting 
prior to drug administration by oral gavage. 
After administration of drug sample, food 
was withheld for further 3-4 h. Animals 
were observed individually at least once 
during first 30 min after dosing, periodical-
ly during first 24 h (with special attention 
during the first 4 h) and daily thereafter for 
a period of 7 days. Daily observations on 
the changes in skin and fur, eyes and mucus 
membrane (nasal), respiratory rate, circula-
tory signs (heart rate and blood pressure), 
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autonomic effects (salivation, lacrimation, 
perspiration, piloerection, urinary inconti-
nence and defecation) and central nervous 
system (ptosis, drowsiness, gait, tremors 
and convulsion) changes were noted 
(OECD, 2002). 
 
Experimental design 
Forty healthy Wistar albino rats of both 
sexes were used for the sub-chronic study. 
They were divided into four groups of 10 
rats per group with each having equal num-
bers of male and female rats. Group I was 
fed with standard diet and water only. 
Group II was fed with standard diet, water 
and 50 mg/kg body weight of BCB, group 
III was fed with standard feed, water and 
100 mg/kg body weight of BCB while 
group IV rats were fed with standard feed, 
water and 200 mg/kg body weight of BCB 
only (Table 1). The drugs were adminis-
tered using a curved, ball-tipped stainless 
steel feeding needle for a period of 28 days. 
 
Table 1: Feeding study 
Group Treatment Dura-
tion 
(Days) 
No of 
rats* 
I Normal feed + 
water 
28 10 rats 
II Feed + 
50 mg/kg bwt  
Baker Cleanser 
Bitters 
28 10 rats 
III Feed + 
100 mg/kg bwt  
Baker Cleanser 
Bitters 
28 10 rats 
IV Feed + 
200 mg/kg bwt  
Baker Cleanser 
Bitters 
28 10 rats 
*10 rats (5 males + 5 females) 
 
Measurement of body weight 
The body weights of the animals were 
evaluated weekly and recorded using a sen-
sitive balance (OECD, 1995). 
 
Sample collection 
At the end of the experimental period, the 
animals were sacrificed using cervical dis-
location method. Blood samples were ob-
tained by cardiac puncture from each rat by 
means of a 2 ml hypodermic syringe and 
needle. The blood samples were introduced 
into clean dry bottles (EDTA bottles) for 
haematological parameters while hepa-
rinized tubes were used to collect blood for 
biochemical estimation. The heparinized 
blood was centrifuged within 5 min of col-
lection at 2500 rpm for 10 minutes. Serum 
was collected into a clean dry sample con-
tainer. The levels of biochemical parame-
ters (ALT, AST, ALP, LDH and bilirubin) 
were estimated using the Humazym MUV-
test kits. The white blood cells (WBC) and 
the differentials were estimated using the 
improved Neubauer counting chambers as 
described by Dacie and Lewis (1991). The 
haemoglobin (Hb) concentration was de-
termined by the Cyameth-haemoglobin 
method while the Packed Cell Volume 
(PCV) was determined by the micro meth-
od also as described by Dacie and Lewis 
(1991). 
 
Lipid peroxidation assay 
The assay method of Hunter et al. 
(1963) modified by Gutteridge and Wilkins 
(1982) was adopted in the estimation of liv-
er malondialdehyde (MDA). One gram of 
liver was homogenized in 10 ml saline solu-
tion and 1.2 ml of the liver homogenate was 
added to 6ml of glacial acetic acid and 6ml 
of 1 % of Thiobarbituric acid (TBA) dis-
solved in 0.2 % sodium hydroxide solution 
in a test tube. This mixture was placed into 
boiling water bath at 100 °C for 15 min, 
then allowed to cool and centrifuged for 
10 min and supernatant were collected. In 
the assay, the clear supernatant (pink col-
ored) was carefully transferred into a cu-
vette and absorbance read on a spectropho-
tometer at wavelength of 532 nm against 
the reagent blank. A molar estimation coef-
ficient of 1.56 x 105 M-1cm-1 was used ac-
cording to the expression of Adam-Vizi and 
Seregi (1982). 
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Statistical analyses 
The results are expressed as mean ± 
standard error of the mean (SEM). One-way 
analysis of variance (ANOVA) was em-
ployed for between and within group com-
parison while student‘s t-test was used for 
paired comparison. 95 % level of signifi-
cance (p≤0.05) was used for the statistical 
analysis. 
 
RESULTS 
There were no BCB extract-treatment 
related mortalities recorded in animals 
treated with a single dose of 2000mg/kg 
body weight. Therefore, the approximate 
lethal dose (LD50) of BCB extract in the 
experimental rats was higher than 
2000 mg/kg. There were no clinical signs in 
the skin and fur, eyes and mucus membrane 
(nasal), respiratory rate, circulatory signs 
(heart rate and blood pressure), autonomic 
effects (salivation, perspiration, piloerec-
tion, urinary incontinence and defecation) 
and central nervous system (ptosis, drowsi-
ness, gait, tremors and convulsion) among 
rats administered 2000 mg kg-1 body weight 
of BCB.  
The effects of BCB on the percentage 
increase in body weight of the control and 
treated rats are shown in Figure 1. General-
ly, a steady increase in the body weight was 
observed in all the treated rats compared 
with control up to the 3rd week. However, a 
drop in the body weight was observed in all 
the treated rats from the 3rd week till the 
end of the 4th week in rats fed 100 and 
200 mg kg-1 body weight of BCB. The drop 
in body weights was from 75.71 % and 
83.33 % in the 3rd week to 74 % and 66 % 
at the end of the 4th week in rats fed 100 
and 200 mg kg-1 body weight of BCB re-
spectively. Surprisingly, the group fed 
50 mg kg-1 body weight of BCB showed a 
percentage increase in body weight from 
75 % in the 3rd week to 80 % at the end of 
the 4th week in a similar fashion as the con-
trol rats from 85 % in the 3rd week to 90 % 
at the end of the 4th week. Table 2 shows a 
summary of the results of the effects of 
BCB on the serum biochemical parameters. 
There was a significant decrease (p≤0.05) 
in the activities of Alanine amino transfer-
ase (ALT), Aspartate amino transferase 
(AST) and fasting blood sugar (FBS) levels 
in the treated rats when compared with the 
control. However, alkaline phosphatase 
(ALP) and lactate dehydrogenase (LDH) 
showed a significant (p≤0.05) increase in 
rats treated with BCB when compared with 
the control. There were however, no signif-
icant (p≤0.05) changes in total bilirubin, 
conjugated bilirubin, malondialdehyde 
(MDA), total protein, cholesterol, triglycer-
ides, creatinine and urea of the treated 
groups compared with control. 
The effect of sub-chronic administration 
of BCB on haematological parameters is 
presented in Table 3. The packed cell vol-
ume (PCV) in treated groups showed a 
marginal decrease when compared with 
control. The platelets of rats administered 
200 mg/kg body weight were significantly 
(p≤0.05) higher when compared with the 
control group. The lymphocytes of rats ad-
ministered 100 mg/kg body weight showed 
a marginal increase whereas a marginal de-
crease in the level of monocytes was also 
observed in the same group when compared 
with the control. However, there was no 
significant difference in WBC and neutro-
phils (Neu) in rats treated with BCB as 
compared to control.  
 
 
 
Figure 1: Percentage increase in body weight 
of the control and rats treated with different 
doses of BCB 
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Table 2: Serum biochemical parameters in rats treated orally with BCB extracts for 28 days 
Dose mg/kg body weight 
Parameters 0 50 100 200 
ALT 144.50±50.20 143.60±44.12 125.80±46.75* 111.80±18.79* 
AST 344.50±14.85 325.28±0.16* 255.80±80.38* 269.20±56.95* 
ALP 20.40±1.70 17.51±3.25* 36.51±2.65 35.80±5.52 
LDH 405.00±21.21 451.01±62.56* 481.41±95.22* 501.40±175.81* 
T.B (µmol/L) 8.75±1.34 6.3±3.5 7.84±4.5 8.26±6.6
C.B (µmol/L) 2.65±0.64 1.34±0.98 1.80±1.64 1.96±1.49 
MDA(µmol/L)x10-6 2.38±6.1 2.05±3.6 1.91±6.7 1.30±2.2
Total protein (g/dl) 41.80±0.85 41.74±5.06 41.64±1.65 41.18±2.42 
Cholesterol (µmol/L) 2.45 ± 0.35 1.93 ± 0.81 1.93 ± 0.39 2.30 ± 0.53 
Triglycerides(mMol/L) 0.90±0.1 0.90±0.26 0.98±0.12 1.27±0.24 
Creatinine (μMol/L) 66.70±4.16 70.00±1.73 69.30±3.79 67.00±3.0 
Urea (µMol/L) 2.20±0.36 1.97±0.21 1.93±0.57 1.90±0.36 
Fasting blood sugar 
(µMol/L) 
9.60±5.98 8.60±0.10 6.73±0.15 5.10±1.08 
Values are expressed as mean ± S.E.M of 10 animals (one-way ANOVA); p>0.05 vs. control group 
(student‘s t-test). *significantly different from control, p<0.05. 
 
 
Table 3: Haematological parameters in rats treated orally with BCB extracts for 28 days 
Dose mg/kg body weight 
Parameters 0 50 100 200 
Hb (mg/dl) 14.25±0.21 14.39±0.38 14.37±0.01 14.75±0.13 
PCV (%) 41.50±2.1 33.50±3.5 33.00±1.42 33.50±3.5 
WBC (x106/μL) 8.15±1.63 9.20±0.42 10.20±0.57 10.70±1.20 
Platelets (x103/μL) 161.00±73.53 169.00±12.73 173.00±9.90 184.00±8.49* 
Neu (%) 13.00±1.41 15.00±2.83 13.00±4.24 16.50±3.53 
Lym (%) 70.50±3.54 70.00±2.83 76.00±4.24 71.50±2.12 
Mon (%) 16.50±2.12 15.00±4.23 11.00±2.83 13.50±3.54 
Values are expressed as mean ± S.E.M of 10 animals (one-way ANOVA); p>0.05 vs. control group 
(student‘s t-test). *significantly different from control, p<0.05. 
 
 
 
DISCUSSION  
Traditional medicine has maintained 
greater popularity all over developing world 
and the use is rapidly on the increase (Das-
wani et al., 2006; Ogbonnia et al., 2010). 
Despite this, the safety of herbal medicine 
use has recently been questioned due to re-
ports of illness and fatalities (Stewart et al., 
1999; Ernst, 2002; Veiga-Junior et al., 
2005; Park et al., 2010); hepatotoxicity 
(Saad et al., 2006) and nephrotoxicity (Co-
syns, 2003; Colson and De Broe, 2005; De-
belle et al., 2008). Although there are many 
traditional herbal medicines available, only 
a few have been verified by clinical trials, 
their efficacy and safety are still questioned 
by consumers (Cheng et al., 2009).  
In the present study, single dose of oral 
administration of BCB to Wistar albino rats 
at 2000 mg/kg body weight had no effect 
on mortality and clinical signs such as 
changes in the skin and fur, eyes and mucus 
membrane (nasal), respiratory rate, circula-
tory signs (heart rate and blood pressure), 
autonomic effects (salivation, perspiration, 
piloerection, urinary incontinence and defe-
cation) and central nervous system (ptosis, 
drowsiness, gait, tremors and convulsion). 
Generally, there was no test substance re-
lated mortality observed at 2000 mg/kg 
(Wallace Hayes, 2001). Therefore, no acute 
toxicity was found in rats treated with BCB 
and the approximate medium acute toxicity 
lethal value (LD50) were determined to be 
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higher than 2000 mg/kg and as such could 
be generally regarded as safe (GRAS). This 
finding is in agreement with Clarke and 
Clarke (1967), who reported that any com-
pound or drug with oral LD50 estimates 
greater than 1000 mg/kg body weight could 
be considered to be of low toxicity and safe. 
However, Zbinden and Roversi (1981) sug-
gested that variables such as animal species, 
strain, age, gender, diet, bedding, ambient 
temperature, caging conditions, and time of 
the day can all affect the LD50 values ob-
tained and as such are considerable uncer-
tainties in extrapolating the LD50 obtained 
for species to other species. This finding is 
suggestive that LD50 may not be considered 
as a biological constant (Zbinden and 
Roversi, 1981). 
The effect of the drug on the percentage 
increase in the body weight was remarkable 
in all the treated groups up till the 3rd week. 
On the other hand, the significant decrease 
observed at the end of the 4th week in the 
groups treated with BCB could be attribut-
ed to the suppression of the animals’ appe-
tite by the extract leading to reduced food 
intake (Ogbonnia et al., 2010). 
Serum marker enzymes are biochemical 
parameters associated with health indices 
and are of diagnostic significance in routine 
clinical evaluation of the state of health.  
Alanine amino transaminase (ALT) and 
Aspartate amino transaminase (AST) are 
largely used in the assessment of liver dam-
age by drugs or any other hepatotoxin 
(Ramaiah, 2011). The liver and heart re-
lease ALT and AST and an elevation in 
their plasma concentrations are indicators 
of liver and heart damage (Wasan et al., 
2001; Mythilypriya et al., 2007). However, 
ALT is more specific to the liver and is thus 
a better parameter for detecting liver injury 
(Ozer et al., 2008). The significant decrease 
observed in the level of ALT and AST is 
suggestive that the polyherbal formula may 
not possess hepatotoxic effect and equally 
could not have caused some toxic effects on 
the heart tissue (Crook, 2006). The protec-
tive effect may be the result of stabilization 
of plasma membrane thereby preserving the 
structural integrity of cell as well as the re-
pair of hepatic tissue damage (Pari and 
Murugan, 2004). The observable increase in 
the level of alkaline phosphatase (ALP) in 
the group administered 100 and 200 mg/kg 
body weight of BCB may be as a result of 
congestion or obstruction of biliary tract, 
which may occur within the liver. ALP ac-
tivity on the other hand is related to the 
functioning of hepatocytes and an increase 
in its activity may be due to its increased 
synthesis in the presence of increased pres-
sure (Manjunatha et al., 2005). However, 
the increased level of lactate dehydrogenase 
(LDH) observed in the present investigation 
apparently indicated the toxic effect of 
Baker Cleansers Bitters in rat. There were 
no significant changes in total protein in 
rats treated with BCB, which suggested that 
there was no sign of impaired renal function 
(Tilkian et al., 1979). Total protein meas-
urements can reflect nutritional status and 
may be used to screen for and help diag-
nose kidney and liver diseases and many 
other conditions (Thierry et al., 2011). The 
near–normal levels of total cholesterol and 
triglycerides observed in groups treated 
with BCB may be attributed to the presence 
of hypolipidemic agents in the polyherbal 
drug (Ogbonnia et al., 2011). Similarly, the 
drug had no adverse effect on the concen-
tration of creatinine and urea. This is sug-
gestive of no kidney damage specifically by 
renal filteration mechanism (Crook, 2006) 
or probably indicates that BCB did not in-
terfere with the renal capacity to excrete 
these metabolites. Therefore, it was evident 
that the drug at doses employed did not 
cause renal impairment or kidney damage. 
Increase in platelets observed in rats treated 
with 200 mg/kg body weight may be at-
tributed to enhanced production and secre-
tion of thrombopoetin the primary regulator 
of platelet production (Kaushansky, 1995) 
by BCB indicating that it has haemostatic 
property (Olaleye et al., 1998).  
In conclusion, the present investigations 
could be regarded as preliminary probes, 
necessitating further studies. The present 
findings have shown that Baker’s Cleanser 
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Bitters is not likely to produce severe toxi-
cological risk. However, a conclusive re-
mark can only be made on the safety profile 
of the drug after further investigations of 
the observations made in this study at the 
cellular level in a chronic study. 
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